Imaging in pleural mesothelioma: A review of Imaging Research Presented at the 9th International Meeting of the International Mesothelioma Interest Group

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 1-6

  Nowak, Anna K ^a,b   Armato, Samuel G ^c   Ceresoli, Giovanni Luca ^d   Yildirim, Huseyin ^e   Francis, Roslyn J ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF CHICAGO   (United States)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Mesothelioma; PET CT; Total glycolytic volume; Tumor response assessment; Tumor staging

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE; PEMETREXED;

CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; IMAGE ANALYSIS; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

DIAGNOSTIC IMAGING; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 77956188584     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.016     Document Type: Review

References (22)

1. Byrne M.J., Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004, 15:257-260.
2. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
3. Zervos M.D., Bizekis CPass H.I. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008, 14:303-309.
4. Metintas M., Ucgun I., Elbek O., Erginel S., et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur J Radiol 2002, 41:1-9.
5. Chakrabarti B., Ryland I., Sheard J., Warburton C.J., Earis J.E. The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest 2006, 129:1549-1555.
6. Heilo A., Stenwig A.E., Solheim O.P. Malignant pleural mesothelioma: US-guided histologic core-needle biopsy. Radiology 1999, 211:657-659.
7. Adams R.F., Gray W., Davies R.J., Gleeson F.V. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest 2001, 120:1798-1802.
8. Metintas M., Ozdemir N., Isiksoy S., Kaya T., et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comp Assist Tom 1995, 19:370-374.
9. Scagliotti G.V., Novello S. State of the art in mesothelioma. Ann Oncol 2005, 16(Suppl 2):ii240-ii245.
10. Heelan R.T., Rusch V.W., Begg C.B., Panicek D.M., et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. Am J Roentgenol 1999, 172:1039-1047.
11. Duysinx B., Nguyen D., Louis R., Cataldo D., et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004, 125:489-493.
12. Kramer H., Pieterman R.M., Slebos D.J., Timens W., et al. PET for the evaluation of pleural thickening observed on CT. J Nucl Med 2004, 45:995-998.
13. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998, 16:145-152.
14. Herndon J.E., Green M.R., Chahinian A.P., Corson J.M., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723-731.
15. Fennell D.A., Parmar A., Shamash J., Evans M.T., et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005, 23:184-189.
16. Francart J., Vaes E., Henrard S., Legrand C., et al. A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009, 45:2304-2311.
17. Boucek J.A., Francis R.J., Jones C.G., Khan N., et al. Assessment of tumour response with (18)F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax-a phantom study. Phys Med Biol 2008, 53:4213-4230.
18. Francis R.J., Byrne M.J., van der Schaaf A.A., Boucek J.A., et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007, 48:1449-1458.
19. Armato S.G., Ogarek J.L., Starkey A., Vogelzang N.J., et al. Variability in mesothelioma tumor response classification. Am J Roentgenol 2006, 186:1000-1006.
20. Oxnard G.R., Armato S.G., 3rdKindler H.L. Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 2006, 52:141-148.
21. Ceresoli G.L., Chiti A., Zucali P.A., Rodari M., et al. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 2006, 24:4587-4593.
22. Schaefer N.G., Veit P., Steinert H., Stahel R.A. Response evaluation by CT and FDG-PET/CT in malignant pleural mesothelioma. J Clin Oncol 2008, 26. Abs 11098.